Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!

List view / Grid view

Informatics

 

ProteinSimple Peggy Sue
ProteinSimple Peggy Sue
product

ProteinSimple Peggy Sue

3 December 2015 | By ProteinSimple

Simple Western™ system that can separate, analyse and quantify proteins based on either size or charge…

DTR Issue 4 2015
DTR Issue 4 2015
article

Drug Target Review – Issue #4 2015

3 December 2015 | By Drug Target Review

Included in this issue: Biomarkers, Mass Spectrometry, Target Validation, Drug Development, Personalised Medicines, Next-Generation Sequencing, Protein Expression, Companion Diagnostics, and much more...

Mass Spectrometry In-Depth Focus 2015
Mass Spectrometry In-Depth Focus 2015
article

Mass Spectrometry In-Depth Focus 2015

3 December 2015 | By , , , ,

In this Mass Spectrometry In-Depth Focus: Michelle M. Hill from University of Queensland discusses Mass spectrometric and systems biology approaches in drug target discovery, and Nicola Burgess-Brown, Rod Chalk, Claire Strain-Damerell and Pravin Mahajan from the Structural Genomics Consortium look at analysing recombinant proteins by mass spectrometry...

The challenges associated with ‘de-risking’ earlystage therapeutic targets
The challenges associated with ‘de-risking’ earlystage therapeutic targets
article

The challenges associated with ‘de-risking’ early-stage therapeutic targets

3 December 2015 | By , , ,

The pharmaceutical industry is searching for novel drug targets that could produce the next generation of ‘first-in-class’ therapeutic agents. The challenge for academia is to identify and translate such targets and to provide starting points and confidence in the underlying science. The aim should be to generate evidence that modulation…

3D printing: A new era for personalised medicines?
3D printing: A new era for personalised medicines?
article

3D printing: A new era for personalised medicines?

3 December 2015 | By

3D printing (3DP) is attracting increasing interest as a new method of fabricating pharmaceutical products, especially with the recent United States Food and Drug Administration (FDA) approval of the first three-dimensional (3D) printed tablet Spritam® (levetiracetam). 3DP is considered to be an additive manufacturing technique, because regardless of their principles of…

product

ProteinSimple NanoPro 1000

2 December 2015 | By ProteinSimple

Simple Western™ system for the characterization of post-translational protein modification by the detection of charge isoforms...

news

Heptares and Pfizer to focus on GPCR targets

30 November 2015 | By Victoria White

Heptares and Pfizer have announced they are to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas...

news

Sleeping sickness project passes 20-month milestone

30 November 2015 | By Victoria White

The aim of the project is to design a drug to inhibit a key parasite enzyme involved in the conversion of blood sugars to energy, to be effective in small doses, even on advanced infections, and kill the parasite...